Chinese Academy of Medical Sciences
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private, Subsidiary
- Established
- 2004-07-08
- Employees
- -
- Market Cap
- -
Characteristics and Treatment Trends of Young Breast Cancer in China
Not yet recruiting
- Conditions
- Breast Cancer
- Interventions
- Procedure: Clinical characteristics, diagnosis and treatment, survival status
- First Posted Date
- 2021-10-05
- Last Posted Date
- 2021-10-13
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 1000
- Registration Number
- NCT05068115
Hypofractionated Post Mastectomy Radiation With Two-Stage Expander/Implant Reconstruction
Not Applicable
Recruiting
- Conditions
- Breast Carcinoma
- Interventions
- Radiation: hypofractionated radiotherapy
- First Posted Date
- 2021-09-16
- Last Posted Date
- 2021-09-16
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 57
- Registration Number
- NCT05045287
- Locations
- 🇨🇳
Jiawei Lu, Shenzhen, Guangdong, China
Real World Study of MPM in China
- Conditions
- TreatmentsDiagnoses DiseaseMalignant Pleural MesotheliomaPrognosis
- First Posted Date
- 2021-09-13
- Last Posted Date
- 2021-09-13
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 500
- Registration Number
- NCT05042557
- Locations
- 🇨🇳
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Screening Plasma HER2 Amplication by Digital PCR in Advanced Breast Cancer Patients Treated With Trastuzumab and Pyrotinib
- First Posted Date
- 2021-08-25
- Last Posted Date
- 2021-08-25
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 68
- Registration Number
- NCT05020964
Fruquintinib Plus Capecitabine as Maintenance Treatment of RAS / BRAF Wild-type Metastatic Colorectal Cancer
- First Posted Date
- 2021-08-23
- Last Posted Date
- 2022-08-18
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 48
- Registration Number
- NCT05016869
- Locations
- 🇨🇳
National Center/Cancer Hospital, China Academy of Medical Science and Peking Union Medical College, Beijing, China
Comparative Effectiveness of Palbociclib Plus AI Versus Fulvestrant for HR+/HER2- ABC
- Conditions
- Hormone Receptor Positive Advanced Breast Cancer
- Interventions
- First Posted Date
- 2021-08-11
- Last Posted Date
- 2022-04-29
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 600
- Registration Number
- NCT05000736
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies
Phase 2
Not yet recruiting
- Conditions
- CD79B Gene MutationCD79A Gene MutationRefractory LymphomaDLBCLMYD88 Gene MutationRelapse
- Interventions
- First Posted Date
- 2021-08-06
- Last Posted Date
- 2021-08-06
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 20
- Registration Number
- NCT04994626
Prophylactic Cranial Irradiation in Extensive-stage Small Cell Lung Cancer
- Conditions
- Extensive-stage Small-cell Lung Cancer
- Interventions
- Radiation: Prophylactic Cranial Irradiation
- First Posted Date
- 2021-07-01
- Last Posted Date
- 2021-09-22
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 100
- Registration Number
- NCT04947774
- Locations
- 🇨🇳
Cancer Insititute and Hosiptal of Chinese Academy of Medical Sciences, Beijing, Beijing, China
TQB2450 Combined With Anlotinib Hydrochloride in the Perioperative Treatment of Hepatocellular Carcinoma Hydrochloride Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With a High Risk of Recurrence or Metastasis
Phase 1
- Conditions
- Patients With Resectable Hepatocellular Carcinoma Who Are at High Risk of Recurrence or Metastasi
- Interventions
- First Posted Date
- 2021-05-17
- Last Posted Date
- 2021-05-17
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 20
- Registration Number
- NCT04888546
- Locations
- 🇨🇳
Chinese Academy of Medical Sciences, Beijing, Beijing, China
Camrelizumab as a Maintenance Therapy After Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma
- First Posted Date
- 2021-04-27
- Last Posted Date
- 2021-04-27
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 155
- Registration Number
- NCT04861467
- Locations
- 🇨🇳
Cancer hospital, Chineses Academy of Medical Sciences, Beijing, China
© Copyright 2025. All Rights Reserved by MedPath